AOL23h
The Oncology Bet Is Already Paying Off For Pfizer
On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the ...
Nasdaq6d
Smart Money Is Betting Big In MRNA Options
Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...
Avidity Biosciences jumps 16%; reaches all-time high
Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...
Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $111.00
Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...
Nasdaq10d
Moderna is Now Oversold (MRNA)
In trading on Monday, shares of Moderna Inc (Symbol: MRNA) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $53.41 per share. By comparison ...
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Business Wire2d
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies ...
Nasdaq6d
Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%
U.S. stocks were higher after the close on Monday, as gains in the Consumer Goods, Financials and Industrials sectors led ...